Introduction
============

Adverse drug event (ADE), the untoward occurrence after exposure to a drug ([@B19]), has been an important public health concern. It is well recognized that pre-marketing randomized controlled trials (RCTs) may not detect all types of ADEs related to a particular drug in clinical practice ([@B25]) due to some limitations ([@B29]). Therefore, FDA encourages the public to voluntarily report any suspicious ADEs to facilitate pharmacovigilance. The FDA Adverse Event Reporting System (FAERS) has become an important resource in post-marketing surveillance for ADEs ([@B38]; [@B13]; [@B32], [@B33]; [@B40]; [@B6]). Commonly used methods to detect ADE signals from FAERS include Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Information Component (IC) and Empirical Bayesian Geometric Mean (EBGM) ([@B2]). For example, a recent study discovered the higher risk of glioblastoma associated with tumor necrosis factor inhibitor by using ROR in FAERS ([@B8]). Since FAERS is a voluntary reporting system, some inherited disadvantages exist such as underreporting and no incidence of ADEs ([@B28]). Other data sources have been studied to assist ADE detection further. Besides social media ([@B17]) and literature ([@B37]), Electronic Medical Record (EMR) has also been paid a lot of attention. E.g., Observational Health Data Sciences and Informatics (OHDSI) has been implementing the international collaboration to conduct clinical outcome research including ADE surveillance using EMR ([@B12]). A majority of the valuable information about clinical outcomes and medication in EMR is captured in clinical narratives ([@B5]). To analyze the clinical narratives, natural language processing (NLP) methods have been employed to extract potential drug-ADE pairs. Signal detection methods such as χ^2^ test or odds ratio have been utilized to rank the pairs ([@B36], [@B35]; [@B11]). The feasibility of using EMR to validate potential drug-ADE pairs detected from FAERS has been demonstrated ([@B34]). However, a majority of the existing studies used data-driven disproportionality analysis with little consideration of confounding variables such as race and gender. Analytic methods to monitor potential ADEs of a drug after prolonged drug exposure are still lacking ([@B26]). In this study, we propose a method aiming to screen potential ADEs from both FAERS and EMR. Specifically, this method incorporates NLP techniques to process EMR, where case-crossover study is employed with consideration of clinical context, including drug indication and temporal information. Subsequently, the potential ADEs from clinical notes and FAERS are evaluated by comparing against SIDER ([@B14]) and Adverse Drug Reaction Classification System (ADReCS) ([@B4]). We test our proposed method for screening potential ADEs for conventional disease-modifying antirheumatic drugs (DMARDs), the cornerstone treatment for Rheumatoid arthritis (RA) patients.

Materials and Methods {#s1}
=====================

Our method for detecting potential ADEs of a drug and indication pair (D, IND) is featured by NLP techniques and case-crossover study design. Specifically it includes three steps: data preparation, signal detection, and validation and hypothesis generation (**Figure [1](#F1){ref-type="fig"}**). In the data preparation step, we apply NLP techniques to extract drugs and clinical outcomes, i.e., problems from EMR. In the signal detection step, a cohort of patients taking drug D for IND is identified from longitudinal EMR data and the corresponding spontaneous reports for the pair (D, IND) in FAERS are extracted. Then, we use case-crossover study design to detect potential ADE signals from EMR. Potential ADE signals from FAERS are detected using ROR. In the validation and hypothesis generation step, signals from EMR and FAERS are then normalized and evaluated using ADE knowledge bases, i.e., ADReCS and SIDER where exact and flexible mapping strategies are used. Existing records of ADEs in the knowledge bases serve as the gold standards and false positives (i.e., signals not present in the knowledge bases) are potential ADEs for further investigation, i.e., hypothesis. The study has been approved as a minimal risk study with Mayo IRB of 13-009317. Only the data of patients with research authorization for using their EMR records have been used.

![Overview of our method for ADE mining from FAERS and EMR. FAERS, FDA Adverse Event Reporting System; EMR, Electronic Medical Record; ADE, Adverse Drug Event; ROR, Reporting Odds Ratio.](fphar-09-00875-g001){#F1}

Data Preparation
----------------

In this study we used the normalized knowledge-enhanced data set AERS-DM ([@B32]) derived from FAERS that is downloadable at our website^[1](#fn01){ref-type="fn"}^. The details and summarization for the data processing can be found in our previous paper ([@B38]; [@B34]).

The EMR data used in our study consists of all patient records at Mayo Clinic Rochester campus with Minnesota research permission over a period of 20 years (January 1995--October 2017). As a majority of the clinical information in EMR is captured in unstructured clinical notes, we process clinical notes using MedXN ([@B27]), which extracts and normalizes medication mentions to RxNorm and MedTagger ([@B30]), which extracts and normalizes clinical concept mentions to the Unified Medical Language System (UMLS). We limit our analysis to the following UMLS semantic types: "Finding(T033)," "Laboratory or Test Result(T034)," "Sign or Symptom(T184)," "Disease or Syndrome(T047)," "Mental or Behavioral Dysfunction (T048)," "Neoplastic Process(T191)" and "Cell or Molecular Dysfunction(T049)," which are related to indications and clinical outcomes.

There are two ADE knowledge bases used in our study. One is SIDER, a resource that aggregates dispersed public information on side effects recorded in public documents and package inserts ([@B14]). In the downloadable files, drugs are coded using STITCH compound identifiers, adverse events and indications are coded using both UMLS and MedDRA lowest level term (LLT). We used SIDER 4.1 in our study.

The other is ADReCS, a more comprehensive ADE resource integrating multiple public medical repositories such as SIDER, DailyMed and ClinicalTrials ([@B4]). ADReCS adopts WHO-ART, MedDRA, and the UMLS as major references for standardization. In this study, ADReCS 1.6 was used.

Signal Detection From AERS-DM
-----------------------------

The associated records of drug D and indication IND are extracted. ROR are computed based on a 2 × 2 contingency table ([@B7]; [@B23]). More specifically the number of reports associated with the drug and ADE is defined as *a*. The number of reports with the drug and without ADE is defined as *b*. The number of reports with other drugs and with ADE is defined as *c*. The number of reports with other drugs and without ADE is defined as *d*. In this analysis, a signal is detected if the lower bound of 95% confidence interval of ROR exceeds 1 ([@B31]). The analysis is implemented in R package PhViD 1.0.6 ([@B1]).
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Signal Detection From EMR
-------------------------

We use case-crossover design to detect signals of association between drug D and potential ADEs for patients with IND from EMR ([@B18]). The case-crossover study is a popular epidemiological study design for which individuals act as their own controls, i.e., comparisons are made within individuals. It has been recommended for pharmacoepidemiological research to leverage EMR data as confounding factors, such as genetics and gender, are well controlled and they do not vary with time ([@B10]).

In this study we conducted unconditional analysis using odds ratio (OR) to detect signals. A potential ADE is detected when the lower bound of the 95% confidence interval of the OR exceeds 1 and *p*-value is less than 0.05.
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**Figure [2](#F2){ref-type="fig"}** defines *a*, *b*, *c*, and *d* for OR calculation in case-crossover study. We use the patient cohort during the observation period before the use of drug D and after the diagnosis of IND as the control, and the same patient cohort during the observation period after the first use until the last use of drugs of interest as the case. In the case group, if an outcome occurs, the patient is counted as "a", otherwise as "b". In the control group, if an outcome occurs, then the patient is counted as "c", otherwise as "d". OR value could be calculated for each outcome using the same patient cohort undergoing drug therapy. Therefore, the patient number in the case group is the same as that in the control group for each outcome.

![Case-crossover study design for potential ADEs of drugs of interest from EMR clinical notes. The observation period before the use of drug is used as the control and the period after drug use is used as the case. P, Patient; RA, rheumatoid arthritis.](fphar-09-00875-g002){#F2}

Validation and Hypothesis Generation
------------------------------------

The ADE obtained from FAERS, EMR, SIDER and ADReCS are coded differently. In order to evaluate the performance of this method for ADE signal detection, we use two mapping strategies to map signals among various data sources. The first strategy is exact mapping. We unify all the codes from various data sources to the UMLS and then conduct direct mapping among sources. The second strategy is flexible mapping combining both exact mapping and the mapping through hierarchical structure. The latter is conducted by leveraging the 5-level hierarchical structure of Medical Dictionary for Regulatory Activities (MedDRA) ([@B3]). Specifically, we expand high-level terms of MedDRA from knowledge bases, i.e., SIDER and ADReCS, to include all sub-level terms and then conduct mapping between knowledge bases and EMR/FAERS. This strategy considers semantic granularity of terms in various sources and tries to obtain as many mappings as possible. **Figure [3](#F3){ref-type="fig"}** shows the examples of these two mapping strategies, where A refers to exact mapping and B refers to flexible mapping. For exact mapping, the term "Abdominal discomfort" is exactly mapped between SIDER/ADReCS and EMR/FAERS as this term appears in those sources. For flexible mapping, if "Skin vasculitis NOS" is detected from EMR/FAERS but only "Vasculitides" exists in the knowledge bases, we first find the lower level term of Vasculitides, i.e., "skin vasculitis NOS" and then map to the signal from EMR/FAERS. Recall, precision, and F1 measures are calculated for FAERS and EMR using the following formula ([@B21]). F1-measure is the harmonic mean of precision and recall ([@B22]) and balances recall and precision ([@B39]).

![Exact and flexible mapping strategies. **(A)** Refers to exact mapping. **(B)** Refers to flexible mapping.](fphar-09-00875-g003){#F3}
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ADE signals detected from FAERS and/or EMR can be validated if they are also captured in SIDER/ADReCS. ADE signals detected from EMR and/or FAERS that are not validated by gold standards could very well likely be false positives but also could be potential novel ADEs, providing hypothesis for future study.

Experiments
===========

We tested the proposed method by detecting potential ADEs for conventional disease-modifying antirheumatic drugs (DMARDs). DMARDs include methotrexate (MTX), sulfasalazine, hydroxychloroquine and leflunomide, which are the cornerstone treatment for Rheumatoid arthritis (RA). An alternative drug choice for RA is biological agents (biologics) such as etanercept, but they are more expensive ([@B15]). DMARDs remain as the primary drug choice for RA treatment ([@B24]).

After data preparation, we extracted RA patients who have been on DMARDs for the treatment of RA. We also extracted associated records of those drugs and indication RA from AERS-DM. We then conducted signal detection for FAERS and EMR.

In validation, two files, meddra_all_label_indications.tsv.gz and meddra_all_label_se.tsv.gz from SIDER 4.1 were used in this study as gold standard for the evaluation of FAERS signals and clinical notes results. Note that not all package inserts with the same ingredient have the same adverse events. Therefore, it's important to extract adverse events from package inserts with indications of "Rheumatoid arthritis" for drugs of interest. Using the STITCH compound identifiers of methotrexate (CID100004112), leflunomide (CID100003899), hydroxychloroquine (CID100003652) and sulfasalazine (CID105353980), package inserts with indications of "Rheumatoid arthritis" were extracted from meddra_all_label_indications.tsv.gz, and then those package inserts were used to identify recorded adverse events of these drugs.

Results
=======

**Table [1](#T1){ref-type="table"}** shows clinical characteristics of RA patients on drugs of interest with ADE reports in FAERS and RA patients on drugs of interest in EMRs. **Supplementary Table [1](#SM6){ref-type="supplementary-material"}** shows the recall, precision, and F1 in detecting ADEs when using ADReCS and SIDER as the gold standards. **Figure [4](#F4){ref-type="fig"}** shows recall (SIDER) greatly increased when combining FAERS with EMR compared with FAERS alone and EMR alone, especially for flexible mapping strategy. For example, recall for detecting ADEs associated with Methotrexate increased to 0.578 (FAERS + EMR) from 0.319 (FAERS) and 0.305 (EMR) using flexible mapping strategy. **Figure [5](#F5){ref-type="fig"}** (SIDER) and **Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}** (ADReCS) show the three-dimensional bubble charts of precision, recall and patient number for three sources, where the bubble sizes represent the patient number. This figure demonstrates that flexible mapping strategy helps to enhance both precision and recall for three sources. **Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}** shows precision (FAERS + EMR) in detecting ADEs improved using ADReCS as gold standard compared with SIDER.

###### 

Clinical characteristics of patients in various sources.

  Source      Gender                           Sulfasalazine \[report number (%)\]   Methotrexate \[report number (%)\]   Leflunomide \[report number (%)\]   Hydroxychloroquine \[report number (%)\]
  ----------- -------------------------------- ------------------------------------- ------------------------------------ ----------------------------------- ------------------------------------------
  **FAERS**   Female (%)                       2,312 (67.6%)                         29,786 (74.2%)                       5,807 (74.4%)                       5,635 (79.1%)
              Male (%)                         894 (26.1)                            7,518 (18.7%)                        1,617 (20.7%)                       1,040 (14.6%)
              F:M ratio                        2.6:1                                 4.0:1                                3.6:1                               5.4:1
              Total                            3,420                                 40,161                               7,820                               7,123
              Female (%)                       1,264 (64.8%)                         4,193 (68.6%)                        1,619 (70.2%)                       3,985 (73.0%)
              Male (%)                         687 (35.2%)                           1,921 (31.4%)                        686 (29.8%)                         1,471 (27.0%)
              F:M ratio                        1.8:1                                 2.2:1                                2.4:1                               2.0:1
              **Race**                                                                                                                                        
              American Indian/Alaskan Native   16                                    33                                   20                                  32
              Asian                            22                                    56                                   16                                  56
              Black or African American        19                                    51                                   16                                  74
              White                            1,729                                 5,385                                2,084                               4,873
              Other                            34                                    94                                   38                                  117
              Unknown                          121                                   467                                  121                                 278
              Choose not to disclose           10                                    28                                   10                                  26
              Total                            1,951                                 6,114                                2,305                               5,456

![Recall in detecting ADEs using SIDER as the gold standard.](fphar-09-00875-g004){#F4}

![Bubble Chart of Precision, Recall and patient number for three sources (SIDER). The *X* axis denotes recall, the *Y* axis denotes precision and the bubble size denotes the number of patients.](fphar-09-00875-g005){#F5}

**Figure [6](#F6){ref-type="fig"}** and **Supplementary Figure [S3](#SM3){ref-type="supplementary-material"}** show the Venn diagrams of ADE signals detected from FAERS and EMR as well as ADEs captured in SIDER, using the flexible mapping strategy and the exact mapping strategy, respectively. In **Figure [6](#F6){ref-type="fig"}**, the overlaps represent the typical ADEs in SIDER that are also detected from FAERS and EMR, e.g., bacterial infection, Leukocytoclastic vasculitis and sepsis for methotrexate and retinopathy for hydroxychloroquine. **Supplementary Figures [S4](#SM4){ref-type="supplementary-material"}**, **[S5](#SM5){ref-type="supplementary-material"}** show the Venn diagram of signals detected from FAERS and EMR with ADEs captured in ADReCS, using the exact mapping strategy and the flexible mapping strategy, respectively. From the Venn diagrams, it can be observed that both FAERS and EMR have a considerable number of detected signals overlapping with known ADEs captured in knowledge bases. However, there is a significant overlap between signals detected from FAERS and signals detected from EMR but not in existing knowledge bases, suggesting potential ADEs for further investigation. The top 10 potential ADEs based on the OR score are listed in **Table [2](#T2){ref-type="table"}**. The disorders shown in bold letters may represent potential confounding factors due to indications. For example, diskitis is likely to be the manifestations of the underlying inflammatory arthritis for which sulfasalazine is being used. Other disorders may be potential ADEs associated with the drug. For example, methotrexate associated malignant melanoma has been confirmed in a recent study ([@B20]). Additionally, signals detected independently by either FAERS or EMR deserve further investigation. For example, FAERS alone detected ADE signal associated with sulfasalazine, i.e., pleural effusion, which has been reported in literature to occur after sulfasalazine use ([@B9])but not recorded in knowledge bases. Hyperparathyroidism associated with methotrexate detected by using EMR alone has also been reported in literature ([@B16]).

![Venn diagram of ADE signals detected from FAERS and EMR and ADEs captured in SIDER using the flexible mapping strategy. Numbers indicate how many ADEs are there in each specific colored area.](fphar-09-00875-g006){#F6}

###### 

Top 10 potential new ADEs detected from FAERS and EMR but not recorded in ADReCS.

  Drugs                ADE AAD ADE signals             OR      *P*-value   Bonferroni-corrected *P*-value
  -------------------- ------------------------------- ------- ----------- --------------------------------
  Sulfasalazine        Postoperative wound infection   8.02    3.60E-14    1.44E-12
                       **Diskitis**                    8.02    3.60E-14    1.44E-12
                       Delayed healing                 6.02    2.47E-18    9.88E-17
                       Organizing pneumonia            4.01    3.82E-13    1.53E-11
                       Lymph node metastasis           4.01    3.82E-13    1.53E-11
                       Finger infection                4.01    3.82E-13    1.53E-11
                       Staphylococcus                  3.01    8.19E-05    0.003276
                       Foot ulcer                      2.67    0.00        0.00
                       Interstitial fibrosis           2.51    6.93E-11    2.77E-09
                       Septic joint                    2.50    0.00        0.00
  Leflunomide          Hospital acquired pneumonia     22.11   1.23E-24    4.92E-23
                       Polymicrobial infection         14.04   1.23E-24    4.92E-23
                       Foot cellulitis                 14.04   0.01        0.40
                       Septic joint                    12.06   7.74E-23    3.10E-21
                       Klebsiella pneumoniae           12.03   7.74E-23    3.10E-21
                       Furunculosis                    12.03   1.69E-20    6.76E-19
                       Pseudomonas pneumonia           10.02   1.72E-26    6.88E-25
                       **Hip dislocation**             9.03    7.05E-18    2.82E-16
                       **Subtrochanteric fracture**    8.01    7.05E-18    2.82E-16
                       Perforated gastric ulcer        8.01    0.02        0.80
  Methotrexate         Lymphoproliferative disorder    34.09   1.05E-12    4.20E-11
                       **Shoulder fracture**           16.02   2.19E-32    8.76E-31
                       Malignant melanoma *in situ*    16.02   2.19E-32    8.76E-31
                       Bacterial pneumonia             16.02   2.19E-32    8.76E-31
                       Hospital acquired pneumonia     14.03   5.39E-07    2.16E-05
                       Varicella zoster                14.02   2.05E-30    8.20E-29
                       B cell lymphoma                 12.04   0.01        0.40
                       **Osteoporotic fracture**       12.02   0.00        0.00
                       Chest congestion                12.02   0.00        0.00
                       **Wrist injury**                12.01   1.47E-28    5.88E-27
  Hydroxychloroquine   Postoperative infection         12.01   7.51E-40    3.00E-38
                       **Rheumatoid arthropathy**      8.01    5.13E-43    2.05E-41
                       Metastatic carcinoma            8.01    5.13E-43    2.05E-41
                       **Hip dislocation**             8.01    5.13E-43    2.05E-41
                       SLE flare                       8.01    5.47E-34    2.19E-32
                       **Lumbar fracture**             8.01    5.47E-34    2.19E-32
                       Injection site reactions        8.01    5.47E-34    2.19E-32
                       Ghon complex                    8.01    5.47E-34    2.19E-32
                       Upper extremity edema           5.00    2.30E-35    9.20E-34
                       **Shoulder dislocation**        5.00    2.30E-35    9.20E-34

Discussion
==========

Drug safety surveillance in clinical practice is important for each drug after introduction on the market. In this study we propose a method for ADE detection from EMR and FAERS and used DMARDs for the treatment of RA as the example case. Some detected ADEs can be confirmed by knowledge bases, and some are potentially new ADEs detected from EHR and/or FAERS but not in existing knowledge bases, warranting further studies for validation.

Researchers have tried to build comprehensive ADE knowledge bases but currently there are no well established ones. One of reasons lies in the fact that post-marketing surveillance is an ongoing process. Though SIDER is included in ADReCS, the comparison of SIDER and ADReCS strengthens our method as some false positives detected from SIDER are true ADEs captured in ADReCS.

The findings from **Supplementary Table [S1](#SM6){ref-type="supplementary-material"}** demonstrated that flexible mapping strategy helped to improve recall, precision and F1 on the whole. One possible reason maybe because EMR clinical narratives contain dense ADE signals in various semantic granularities where exact mapping strategy may miss some mappings. ADE signals detected from EMR and/or FAERS that are not validated by gold standards could very well likely be false positives but also could be potential novel ADEs.

In our previous study, we demonstrated the feasibility of EMR in validating potential ADEs from FAERS ([@B34]). The present study focuses on a method for ADE detection from EMR and FAERS. Our method offers multiple contributions to the community. First, we use NLP techniques to extract treatment outcome information captured in unstructured text and standardize the information using UMLS codes which enables us to detect potential ADEs not captured in structured EMR data and at the same time, allows us to adopt the flexible mapping strategy to combine signals detected from diverse data sources. Secondly, our method adopts case-crossover design with drug use as exposure. This method can automatically eliminate many underlying confounding factors and false positive signals, especially after the incorporation of temporal information of treatment outcomes and drug uses.

A previous study investigated a large-scale signal boosting approach combining FAERS and MEDLINE articles ([@B37]), where pairs appearing in both FAERS and MEDLINE sentences had the highest precision of 0.140 compared to 0.025 (FAERS) and 0.111 (FAERS + abstract), recall varied from 0.507 (FAERS), 0.138 (FAERS and sentences) to 0.234 (FAERS + abstract), and F1 varied from 0.045 (FAERS), 0.139 (FAERS and sentences) to 0.151 (FAERS + abstract). The study used SIDER as the gold standard, and the findings represented the performance level for large-scale databases like FAERS and MEDLINE as roughly from 0.025 to 0.507. Our results showed similar performances using another large-scale database, i.e., EMR.

Various sources of ADEs could exert different effects with unique advantages. FAERS includes voluntary spontaneous reports that may not capture the true incidence information. However, it contains millions of ADE-relevant records. Meanwhile, as a real world data source with the capability to yield valuable insights, EMR contains abundant information on treatment outcome and drug exposure. Therefore, a higher number of false positives by combining EMR and FAERS implies more potential novel ADEs detected. In addition, ADE signals detected by both FAERS and EMR can be prioritized for follow-up epidemiological or laboratory studies.

Limitations of our study include the following. First, our experiment used EMR data from a single institution. Secondly, the design of the case crossover studies did not exclude complex drug exposure situation and drug--drug interactions, and the carry over effects of previous drugs during the "control" period and other time-varying confounders that could result in ADE such as new comorbidities of patients. Additionally, the semantic granularity difference across diverse data sources has not been fully addressed even through the flexible mapping strategy. We plan to tackle those limitations by using EMR data from multiple institutions and investigate strategies to exclude complex drug exposure situation. Also, we can adopt semantic similarity to address the semantic granularity difference issue.

Conclusion
==========

We proposed a method for detecting potential ADEs associated with drugs by combining two data sources: FAERS and EMR, and evaluated their performances using two ADE knowledge bases: ADReCS and SIDER. The use of NLP and the innovative adoption of case-crossover study design enable us to detected signals from large-scale EMR data. Findings showed that Recall greatly increased when combining FAERS with EMR compared with FAERS alone and EMR alone, especially for flexible mapping strategy. Precision (FAERS + EMR) in detecting ADEs improved using ADReCS as gold standard compared with SIDER. In addition, signals detected from EMR have considerably overlapped with signals detected from FAERS or ADE knowledge bases, implying the importance of EMR for pharmacovigilance. ADE signals detected from EMR and/or FAERS but not in existing knowledge bases provide hypothesis for future study.
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Bubble chart of precision, recall and patient number for three sources (ADReCS). The *X* axis denotes recall, the *Y* axis denotes precision and the bubble size denotes the number of patients.
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Click here for additional data file.

###### 

Precision of FAERS + EMR in detecting ADEs when using ADReCS and SIDER as the gold standards.
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Click here for additional data file.

###### 

Venn diagram of ADE signals detected from FAERS and EMR and ADEs captured in SIDER using the exact mapping strategy. Numbers indicate how many ADEs are there in each specific colored area.
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Click here for additional data file.

###### 

Venn diagram of ADE signals detected from FAERS and EMR and ADEs captured in ADReCS using the exact mapping strategy. Numbers indicate how many ADEs are there in each specific colored area.
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Click here for additional data file.

###### 

Venn diagram of ADE signals detected from FAERS and EMR and ADEs captured in ADReCS using the flexible mapping strategy. Numbers indicate how many ADEs are there in each specific colored area.
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Click here for additional data file.

###### 

Performance of FAERS, EMR and FAERS + EMR in detecting ADEs when using ADReCS and SIDER as the gold standards.
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Click here for additional data file.
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